All Trials

An Open-Label, Multicenter, Phase Ib Dose Randomization Study of Bulumtatug Furvedotin (BFv; 9MW2821) in Subjects With Recurrent or Metastatic Triple-Negative Breast Cancer Previously Treated With Antibody-Drug Conjugates

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent/metastatic triple‑negative breast cancer previously treated with a taxane and a topoisomerase‑inhibitor ADC (ECOG 0–1) receive bulumtatug fuvedotin (9MW2821), a Nectin‑4–targeted MMAE antibody‑drug conjugate, at two dose levels. Excludes prior MMAE‑based or Nectin‑4 ADC exposure and requires measurable disease and available tissue; explores efficacy with biomarker correlations (including Nectin‑4 expression).

ClinicalTrials.gov ID: NCT06908928

A Phase 1b/2, Open-Label, Multicohort Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with previously treated, locally advanced/metastatic breast cancer across HER2+ to HER2-low/ultralow (cohorts by HER2 and HR status, generally after standard HER2 therapies and/or CDK4/6i, PARPi, checkpoint inhibitors, and prior T-DXd as applicable). Single-arm disitamab vedotin (HER2-targeted MMAE antibody–drug conjugate) IV q2w until progression; excludes active CNS disease and prior MMAE ADCs.

ClinicalTrials.gov ID: NCT06966453

A Phase Ib/II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination With Giredestrant in Comparison With Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer Who Have Previously Progressed During or After a CDK4/6 Inhibitor

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ER-positive, HER2-negative locally advanced/metastatic breast cancer who have progressed on prior CDK4/6 inhibitor plus endocrine therapy (ECOG 0–1) are enrolled to receive GDC-4198—an oral next-generation cyclin-dependent kinase inhibitor with potent CDK4 and additional CDK2 activity—alone or with the oral SERD giredestrant, and in Phase II are randomized to GDC-4198 + giredestrant (two dose levels) versus abemaciclib + giredestrant. Excludes visceral crisis requiring chemotherapy and prior chemotherapy for metastatic disease.

ClinicalTrials.gov ID: NCT07100106

A Phase I/II, Randomized, Multi-site Trial to Investigate the Efficacy and Safety of BNT314 in Combination With BNT327 and Chemotherapy in Participants With Metastatic Colorectal Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable, MSS/pMMR metastatic colorectal adenocarcinoma (ECOG 0–1) are treated with BNT314 (bispecific EpCAM×4‑1BB agonist delivering EpCAM-restricted costimulation) plus BNT327 (bispecific PD‑L1×VEGF‑A inhibitor) with standard chemotherapy across lines of therapy, with Phase 2 randomization versus bevacizumab + chemotherapy or BNT327 + chemotherapy. Excludes MSI‑H/dMMR and prior EpCAM/4‑1BB, checkpoint inhibitor, or PD‑(L)1/VEGF bispecific exposure, and patients with uncontrolled CNS disease or significant cardiovascular/autoimmune risks.

ClinicalTrials.gov ID: NCT07079631

Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with newly diagnosed metastatic colorectal adenocarcinoma starting first-line q2‑week chemotherapy (FOLFOX/FOLFIRI/FOLFIRINOX ± bevacizumab/other biologics), ECOG 0–2 and BMI ≤29, are randomized at cycle 2 to daily subcutaneous TCMCB07 (mifomelatide) vs placebo for 12 weeks to preserve body weight and composition. TCMCB07 is a brain-penetrant cyclic peptide antagonist of MC4R/MC3R intended to counter cancer/chemo‑related anorexia and hypermetabolism; safety and weight change at 12 weeks are primary outcomes.

ClinicalTrials.gov ID: NCT06937177

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/metastatic GI cancers—previously treated colorectal or pancreatic ductal adenocarcinoma, and biliary tract cancers (treatment‑naive or previously treated)—receive sacituzumab tirumotecan (MK‑2870), a TROP2‑targeted antibody–drug conjugate delivering a belotecan‑derived topoisomerase I inhibitor, as monotherapy or combined with 5‑FU/leucovorin, or with cisplatin plus pembrolizumab. Excludes significant ophthalmologic disease and prior steroid‑requiring ILD/pneumonitis; prior therapy toxicities must have resolved.

ClinicalTrials.gov ID: NCT06428409

A Multi-Center Phase I Dose Escalation Study of Avutometinib, a RAF/MEK Clamp, in Pediatric Patients With Refractory or Recurrent Solid Tumors Harboring Activating MAPK Pathway Alterations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Pediatric and young adult patients (3–30 years) with refractory or recurrent solid tumors, including CNS tumors, harboring activating MAPK pathway alterations (e.g., BRAF/RAF fusions or mutations, RAS, PTPN11, SOS1/2, NF1 loss) receive oral avutometinib. Avutometinib is a first-in-class RAF/MEK “clamp” that allosterically inhibits RAF and MEK to suppress MAPK signaling; prior RAF/MEK monotherapy is allowed, and key exclusions include significant ocular, cardiac, or rhabdomyolysis risk.

ClinicalTrials.gov ID: NCT06104488

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults and adolescents (≥15) with recurrent IDH1/2-mutant diffuse glioma (WHO grade 2–4) after prior radiation and/or chemotherapy receive intermittent oral zotiraciclib monotherapy. Zotiraciclib is an investigational multi-kinase, CDK9-focused inhibitor that suppresses RNA Pol II–dependent transcription (e.g., MCL-1/MYC pathways); a surgical PD cohort gets a single pre-resection dose with post-op resumption.

ClinicalTrials.gov ID: NCT05588141

A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 With Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with first-recurrent, supratentorial, IDH-wildtype GBM (KPS ≥70%) receive the investigational CMV-targeted vaccine VBI-1901—a virus-like particle presenting gB (humoral) and pp65 (T-cell) antigens—given with GM-CSF or AS01B; the randomized extension compares VBI-1901 + GM-CSF versus single-agent nitrosourea (lomustine or carmustine). Key exclusions include high-dose steroids, significant CMV viremia, autoimmune/immunosuppressive conditions, multifocal/leptomeningeal disease, and IDH-mutant tumors.

ClinicalTrials.gov ID: NCT03382977

DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Single-arm maintenance trial for children and young adults (<40) with relapsed/refractory Ewing sarcoma or osteosarcoma who are now NED after completing relapse therapy, ECOG 0–2, with adequate organ function. Participants receive oral DFMO (eflornithine), an irreversible ornithine decarboxylase inhibitor that depletes polyamines, given twice daily in 28‑day cycles for up to 2 years to delay recurrence.

ClinicalTrials.gov ID: NCT06892678